Lipid-lowering therapy and outcomes in heart failure

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 12, Issue 1, 2007, Pages 27-35

  Ray, Joel G ^c   Norris, Colleen M ^a   Udell, Jacob A ^b   Tsuyuki, Ross T ^d   McAlister, Finlay A ^a   Knudtson, Merril L ^a   Ghali, William A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d NONE

Author keywords

Acute myocardial infarction; Arrhythmia; Atorvastatin; Death; Heart failure; Mortality; Pravastatin; Simvastatin; Statin; Stroke

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DATA BASE; DEATH; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; SURVIVAL;

AGED; ANTILIPEMIC AGENTS; COHORT STUDIES; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART FUNCTION TESTS; HEART RATE; HUMANS; MALE; PROSPECTIVE STUDIES; REVIEW LITERATURE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 34247642089     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248407299839     Document Type: Article

References (35)

1. Gheorghiade M., Bonow RO Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998 ; 97: 282-289.
2. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999 ; 20: 421-428.
3. Cleland JG, Thygesen K., Uretsky BF,, et al. ATLAS investigators. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J. 2001 ; 22: 1601-1612.
4. Baigent C., Keech A., Kearney PM,, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366: 1267-1278.
5. Node K., Fujita M., Kitakaze M., Hori M., Liao JK Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003 ; 108: 839-843.
6. Laufs U., Wassmann S., Schackmann S., Heeschen C., Bohm M., Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol. 2004 ; 93: 103-108.
7. Kjekshus J., Pedersen TR, Olsson AG, Faergeman O., Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997 ; 3: 249-254.
8. Mitchell LB, Powell JL, Gillis AM, Kehl V., Hallstrom AP Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. JACC. 2003 ; 42: 81-87.
9. White HD, Aylward PE, Huang Z.,, et al. VALIANT Investigators. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation. 2005 ; 112: 3391-3399.
10. Masoudi FA, Baillie CA, Wang Y., et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med. 2005 ; 165: 2069-2076.
11. Ray JG, Mamdani M., Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001 ; 161: 1405-1410.
12. Ghali WA, Faris PD, Galbraith PD,, et al. Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Sex differences in access to coronary revascularization after cardiac catheterization: importance of detailed clinical data. Ann Intern Med. 2002 ; 136: 723-732.
13. Rosenbaum PR, Rubin DB The central role of the propensity score in observational studies for causal effects. Biometrika. 1983 ; 70: 41-55.
14. Tsuyuki RT, Shrive FM, Galbraith PD, Knudtson ML, Graham MM ; APPROACH Investigators. Revascularization in patients with heart failure. CMAJ. 2006 ; 175: 361-365.
15. Cacciatore F., Abete P., Mazzella F., et al. Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur J Clin Invest. 2005 ; 35: 723-730.
16. Goldberg HL, Borer JS, Moses JW, Fisher J., Cohen B., Skelly NT Digital subtraction intravenous left ventricular angiography: comparison with conventional intraventricular angiography. J Am Coll Cardiol. 1983 ; 1: 858-862.
17. Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002 ; 90: 147-149.
18. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998 ; 129: 681-689.
19. de Lemos JA, Blazing MA, Wiviott SD,, et al. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA. 2004 ; 292: 1307-1316.
20. Sever PS, Dahlof B., Poulter NR,, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in the Ango-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2005 ; 361: 1149-1158.
21. Schwartz GG, Olsson AG, Ezekowitz MD,, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001 ; 285: 1711-1718.
22. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002 ; 288: 2998-3007.
23. Shepherd J., Blauw GJ, Murphy MB,, et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER). a randomized controlled trial. Lancet. 2002 ; 360: 1623-1630.
24. LaRosa JC, Grundy SM, Waters DD,, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 ; 352: 1425-1435.
25. Pedersen TR, Faergeman O., Kastelein JJ,, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005 ; 294: 2437-2445.
26. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996 ; 335: 1001-1009.
27. Mozaffarian D., Nye R., Levy WC Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004 ; 93: 1124-1129.
28. Horwich TB, MacLellan WR, Fonarow GC Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. JACC. 2004 ; 43: 642-628.
29. Ray JG, Gong Y., Sykora K., Tu JV Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med. 2005 ; 165: 62-67.
30. Fukuta H., Sane DC, Brucks S., Little WC Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005 ; 112: 357-363.
31. Foody JM, Shah R., Galusha D., Masoudi FA, Havranek EP Krumholz HM. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006 ; 113: 1086-1092.
32. Udell JA, Ray JG Primary and secondary prevention of heart failure with statins. Expert Rev Cardiovasc Ther. 2006 ; 4: 917-926.
33. Kjekshus J., Dunselman P., Blideskog M.,, et al. CORONA Study Group. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA). study design and baseline characteristics. Eur J Heart Fail. 2005 ; 7: 1059-1069.
34. Tavazzi L., Tognoni G., Franzosi MG,, et al. GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004 ; 6: 635-641.
35. Colhoun HM, Betteridge DJ, Durrington PN,, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): a multicentre randomized placebo-controlled trial. Lancet. 2004 ; 364: 685-696.